Avalo Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2014 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Avalo Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2014 to Q4 2023.
  • Avalo Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $56.9M, a 8.71% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $56.9M +$4.56M +8.71% Dec 31, 2023 10-K 2024-03-29
Q4 2022 $52.3M +$8.89M +20.5% Dec 31, 2022 10-K 2024-03-29
Q4 2021 $43.5M +$19.1M +78.5% Dec 31, 2021 10-K 2023-03-29
Q4 2020 $24.3M +$10M +69.7% Dec 31, 2020 10-K 2022-03-02
Q4 2019 $14.3M +$3.62M +33.7% Dec 31, 2019 10-K 2021-03-08
Q4 2018 $10.7M +$6.7M +167% Dec 31, 2018 10-K 2020-03-11
Q4 2017 $4.02M -$26.9M -87% Dec 31, 2017 10-K 2019-03-18
Q4 2016 $30.9M +$6.55M +26.9% Dec 31, 2016 10-K 2018-04-02
Q4 2015 $24.3M +$4.83M +24.8% Dec 31, 2015 10-K 2017-03-14
Q4 2014 $19.5M Dec 31, 2014 10-K 2016-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.